Recommendation of Final Dividend
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics board has recommended a final dividend of INR 2 per equity share (40% of face value of INR 5) for FY2025-26, subject to shareholder approval at the ensuing AGM. For the year ended March 2026, standalone profit grew 24% to INR 1,026.75 million from INR 828.08 million, while consolidated profit rose 30.7% to INR 1,014.31 million from INR 776.08 million. Revenue from operations increased to INR 7,727.74 million on consolidated basis. EPS improved to INR 31.69 (standalone) and INR 31.30 (consolidated). The company also saw fair value gain of INR 258.75 million from derecognition of associate Apulki Healthcare. Income tax demands of INR 626.90 million remain under appeal.
The dividend signals continued shareholder returns; however, the INR 2 per share payout is modest relative to earnings, reflecting retention of cash for expansion. Shareholders should note this is a recommendation pending AGM approval.